Melanoma in situ: Part II. Histopathology, treatment, and clinical management

J Am Acad Dermatol. 2015 Aug;73(2):193-203; quiz 203-4. doi: 10.1016/j.jaad.2015.03.057.

Abstract

Melanoma in situ (MIS) poses special challenges with regard to histopathology, treatment, and clinical management. The negligible mortality and normal life expectancy associated with patients with MIS should guide treatment for this tumor. Similarly, the approach to treatment should take into account the potential for MIS to transform into invasive melanoma, which has a significant impact on morbidity and mortality. Part II of this continuing medical education article reviews the histologic features, treatment, and management of MIS.

Keywords: lentigo maligna; melanoma; melanoma in situ.

Publication types

  • Review

MeSH terms

  • Administration, Topical
  • Aminoquinolines / therapeutic use
  • Biopsy, Needle
  • Carcinoma in Situ / pathology*
  • Carcinoma in Situ / therapy*
  • Female
  • Humans
  • Imiquimod
  • Immunohistochemistry
  • Immunotherapy / methods
  • Injections, Intralesional
  • Interferon-alpha / administration & dosage
  • Laser Therapy / methods
  • Male
  • Melanoma / pathology*
  • Melanoma / therapy*
  • Melanoma, Cutaneous Malignant
  • Mohs Surgery / methods
  • Neoplasm Invasiveness / pathology
  • Neoplasm Staging
  • Prognosis
  • Randomized Controlled Trials as Topic
  • Skin Neoplasms / pathology*
  • Skin Neoplasms / therapy*
  • Treatment Outcome

Substances

  • Aminoquinolines
  • Interferon-alpha
  • Imiquimod